Let's Talk
Let’s Talk

Author: gaurav

Sapient Featured in Bruker Press Release Announcing timsTOF Innovations at ASMS 2022

“Sapient’s proprietary, next-generation rapid LC-MS (rLC-MS) technologies leverage the unique bioanalytical capabilities of the Bruker timsTOF Pro 2 system and enable nontargeted capture and measure of more than 11,000 circulating small molecule biomarkers – including thousands of yet uncharacterized factors – in a human biosample in less than one minute. These technologies are embedded within an integrated discovery pipeline… Continue reading Sapient Featured in Bruker Press Release Announcing timsTOF Innovations at ASMS 2022

Data ≠ Insight: Improving Metabolomics Data Interpretation

Untargeted biomarker discovery aims to uncover previously unknown factors that associate with biologically relevant changes in human health and disease, such as those related to disease progression or treatment response. Most diseases, while singularly defined pathologically, actually represent diverse groupings of contributing factors and biological pathways. Identifying novel biomarkers can help to elucidate more of… Continue reading Data ≠ Insight: Improving Metabolomics Data Interpretation

Identifying Non-Invasive Biomarkers of Target Engagement

Now On Demand | Hosted by AAPS Watch Now A key aspect of the drug discovery pipeline is evaluation of in vivo target engagement and subsequent biological response. While measures of target engagement are often optimized in cellular and preclinical systems, direct measures of tissue target engagement are often limited in human subjects as part of… Continue reading Identifying Non-Invasive Biomarkers of Target Engagement

On the Mark? Identifying Biomarkers of Target Engagement

Retrospective analyses conducted by major pharmaceutical companies on their drug pipelines have revealed that close to one-fifth of Phase II failures due to efficacy did not conclusively demonstrate adequate target exposure. This statistic emphasizes the importance of identifying target engagement biomarkers, which report on drug-target interactions and the cascade of biological changes that occur when a drug… Continue reading On the Mark? Identifying Biomarkers of Target Engagement

What is Discovery at Scale? Multiplying the Rate of Nontargeted Biomarker Profiling

A drug candidate with an associated biomarker is 2−10x more likely to obtain FDA approval. Why? Because biomarkers help to stratify patient populations by elucidating the involvement of specific genes, proteins, and molecular alterations that give rise to their disease state. Therapies can then be aligned with patients most likely to benefit. The challenge is… Continue reading What is Discovery at Scale? Multiplying the Rate of Nontargeted Biomarker Profiling

Smaller, Faster & More Effective: Clinical Trial Enrichment Using Circulating Biomarkers

Now On Demand | Hosted by AAPS Watch Now Diseases are singularly defined but often represent varied groupings of contributing factors and pathways that ultimately produce a shared pathology. Heterogeneous molecular pathogenesis creates heterogeneity in treatment responsiveness, which in turn drives up clinical trial size, timing, cost, and failure rates. For agents that ultimately achieve FDA… Continue reading Smaller, Faster & More Effective: Clinical Trial Enrichment Using Circulating Biomarkers

Harnessing the Human Microbiome for Discovery

Learn about RExMap and our methods to advance biomarker-based discovery of microbially derived metabolites.

Sapient Joins the Foundation for the National Institutes of Health Biomarkers Consortium

San Diego, CA—Sapient, a biomarker discovery organization transforming drug development through rapid, large-scale biomarker profiling, has joined the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium, the preeminent group of public-private partners focused on identifying, developing, and qualifying biomarkers to improve drug development and regulatory decision-making. Sapient’s Philip Worboys, PhD, Head of Translational Science,… Continue reading Sapient Joins the Foundation for the National Institutes of Health Biomarkers Consortium

Comparison of Omics Techniques and Biomarker Types

High throughput technologies can now capture and measure a huge number of biological molecules within a single human cell or tissue, enabling clearer and more complete views of underlying biology and supporting development of molecularly targeted drug therapies. These molecules are found at the gene, protein, and metabolic level, giving rise to multiple ‘omics’ disciplines.… Continue reading Comparison of Omics Techniques and Biomarker Types

Discovery of Biomarker to Predict Immunotherapy Related Autoimmunity

Immunotherapy has transformed the treatment of solid organ cancers, rapidly becoming a first line therapy with transformative durable response. While immunotherapies have favorable toxicity profiles compared to traditional chemotherapies, immunotherapy is associated with the development of immune-related adverse events (irAEs), an autoimmune condition incited by activation of the immune system. 20% to 60% of patients receiving… Continue reading Discovery of Biomarker to Predict Immunotherapy Related Autoimmunity

10421 Wateridge Circle, Suite 100
San Diego, CA 92121

discover@sapient.bio
858.290.7010

Linkedin Youtube
SERVICES
APPLICATIONS
PARTNERING
RESOURCES
ABOUT
BOOK A MEETING
Book a Meeting

© 2024 Sapient Bioanalytics, LLC. All rights reserved.

SAPIENT, the SAPIENT Logo, ACCELERATE HUMAN DISCOVERY, and SPECIFICITY AT SCALE are trademarks of Sapient Bioanalytics, LLC

Let's Talk